b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">29131988</PMID>\n        <DateCompleted>\n            <Year>2018</Year>\n            <Month>07</Month>\n            <Day>31</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2018</Year>\n            <Month>07</Month>\n            <Day>31</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1532-3080</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>37</Volume>\n                    <PubDate>\n                        <Year>2018</Year>\n                        <Month>Feb</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Breast (Edinburgh, Scotland)</Title>\n                <ISOAbbreviation>Breast</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Treatment adoption and relative effectiveness of aromatase inhibitors compared to tamoxifen in early breast cancer: A multi-institutional observational study.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>107-113</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="pii" ValidYN="Y">S0960-9776(17)30773-7</ELocationID>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.breast.2017.11.003</ELocationID>\n            <Abstract>\n                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Since 2005, aromatase inhibitors (AIs) have been the adjuvant treatment of choice for postmenopausal women with early breast cancer (BC). In this study we characterize the adoption of AIs in Portugal, variables associated with treatment administration, and compare its effectiveness (either in monotherapy or sequential therapy) to tamoxifen monotherapy (TAM).</AbstractText>\n                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">This was a retrospective cohort study that included postmenopausal women with stage I-III hormone receptor (HR) positive BC diagnosed from 2006 to 2008 and treated with adjuvant endocrine therapy in four participating institutions.</AbstractText>\n                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 1283 eligible patients, 527 (41%) received an AI (16% as monotherapy, 25% as sequential therapy) and 756 (59%) TAM. Patients treated with AI had less differentiated tumors, with higher TNM stage, and were more frequently HER2-positive. Use of AI also differed by center (use range from 33% to 75%, p\xc2\xa0&lt;\xc2\xa00.001). With a median follow-up of 6.3 years and controlling for clinicopathological and treatment characteristics, treatment with AI had a better overall survival (OS) when compared with TAM (adjusted-HR 0.55, 95% CI 0.37-0.81).</AbstractText>\n                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">AIs were successfully introduced as adjuvant treatment for HR-positive BC in Portuguese hospitals. Its use was influenced by tumor and patient characteristics, but also center of care. In this large cohort, AI use was associated with an OS benefit.</AbstractText>\n                <CopyrightInformation>Copyright \xc2\xa9 2017 Elsevier Ltd. All rights reserved.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Ferreira</LastName>\n                    <ForeName>Arlindo R</ForeName>\n                    <Initials>AR</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Hospital de Santa Maria, Centro Hospitalar de Lisboa Norte, Av. Prof. Egas Moniz, 1649-035 Lisbon, Portugal; Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-035 Lisbon, Portugal.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Palha</LastName>\n                    <ForeName>Ana</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Hospital de Santa Maria, Centro Hospitalar de Lisboa Norte, Av. Prof. Egas Moniz, 1649-035 Lisbon, Portugal.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Correia</LastName>\n                    <ForeName>Lurdes</ForeName>\n                    <Initials>L</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Hospital de Santa Maria, Centro Hospitalar de Lisboa Norte, Av. Prof. Egas Moniz, 1649-035 Lisbon, Portugal.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Filipe</LastName>\n                    <ForeName>Pedro</ForeName>\n                    <Initials>P</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Hospital de Santa Maria, Centro Hospitalar de Lisboa Norte, Av. Prof. Egas Moniz, 1649-035 Lisbon, Portugal.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Rodrigues</LastName>\n                    <ForeName>Vasco</ForeName>\n                    <Initials>V</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Hospital de Santa Maria, Centro Hospitalar de Lisboa Norte, Av. Prof. Egas Moniz, 1649-035 Lisbon, Portugal.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Miranda</LastName>\n                    <ForeName>Ana</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Registo Oncol\xc3\xb3gico Regional do Sul, Instituto Portugu\xc3\xaas de Oncologia F. G. de Lisboa, R. Prof. Lima Basto, 1099-023 Lisbon, Portugal.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Andr\xc3\xa9</LastName>\n                    <ForeName>Ros\xc3\xa1rio</ForeName>\n                    <Initials>R</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Registo Oncol\xc3\xb3gico Regional do Sul, Instituto Portugu\xc3\xaas de Oncologia F. G. de Lisboa, R. Prof. Lima Basto, 1099-023 Lisbon, Portugal.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Fernandes</LastName>\n                    <ForeName>Jo\xc3\xa3o</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Hospitais CUF Lisboa, R. M\xc3\xa1rio Botas, 1998-018 Lisbon, Portugal.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Gouveia</LastName>\n                    <ForeName>Joaquim</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Hospitais CUF Lisboa, R. M\xc3\xa1rio Botas, 1998-018 Lisbon, Portugal.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Passos-Coelho</LastName>\n                    <ForeName>Jos\xc3\xa9 L</ForeName>\n                    <Initials>JL</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Hospital da Luz, Avenida Lus\xc3\xadada, 100, 1500-650 Lisbon, Portugal.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Moreira</LastName>\n                    <ForeName>Ant\xc3\xb3nio</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Instituto Portugu\xc3\xaas de Oncologia F. G. de Lisboa, R. Prof. Lima Basto, 1099-023 Lisbon, Portugal.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Brito</LastName>\n                    <ForeName>Margarida</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Instituto Portugu\xc3\xaas de Oncologia F. G. de Lisboa, R. Prof. Lima Basto, 1099-023 Lisbon, Portugal.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Ribeiro</LastName>\n                    <ForeName>Joana</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Funda\xc3\xa7\xc3\xa3o Champalimaud, Av. Bras\xc3\xadlia, 1400-038 Lisbon, Portugal.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Metzger-Filho</LastName>\n                    <ForeName>Otto</ForeName>\n                    <Initials>O</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Lin</LastName>\n                    <ForeName>Nancy U</ForeName>\n                    <Initials>NU</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Costa</LastName>\n                    <ForeName>Lu\xc3\xads</ForeName>\n                    <Initials>L</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Hospital de Santa Maria, Centro Hospitalar de Lisboa Norte, Av. Prof. Egas Moniz, 1649-035 Lisbon, Portugal; Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-035 Lisbon, Portugal.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Vaz-Luis</LastName>\n                    <ForeName>In\xc3\xaas</ForeName>\n                    <Initials>I</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Institut Gustave Roussy, Unit INSERM 981, 114 Rue Edouard Vaillant, 94800 Villejuif, France; Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA. Electronic address: Ines-Maria.Vaz-Duarte-Luis@gustaveroussy.fr.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D003160">Comparative Study</PublicationType>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D016448">Multicenter Study</PublicationType>\n                <PublicationType UI="D064888">Observational Study</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2017</Year>\n                <Month>11</Month>\n                <Day>10</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>Netherlands</Country>\n            <MedlineTA>Breast</MedlineTA>\n            <NlmUniqueID>9213011</NlmUniqueID>\n            <ISSNLinking>0960-9776</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D018931">Antineoplastic Agents, Hormonal</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D047072">Aromatase Inhibitors</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D011980">Receptors, Progesterone</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>094ZI81Y45</RegistryNumber>\n                <NameOfSubstance UI="D013629">Tamoxifen</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.7.10.1</RegistryNumber>\n                <NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.7.10.1</RegistryNumber>\n                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D018931" MajorTopicYN="N">Antineoplastic Agents, Hormonal</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D047072" MajorTopicYN="N">Aromatase Inhibitors</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D060787" MajorTopicYN="N">Neoplasm Grading</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011174" MajorTopicYN="N">Portugal</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011980" MajorTopicYN="N">Receptors, Progesterone</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D013629" MajorTopicYN="N">Tamoxifen</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">Aromatase inhibitors</Keyword>\n            <Keyword MajorTopicYN="N">Early breast cancer</Keyword>\n            <Keyword MajorTopicYN="N">Tamoxifen</Keyword>\n            <Keyword MajorTopicYN="N">Treatment effectiveness</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2017</Year>\n                <Month>06</Month>\n                <Day>12</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="revised">\n                <Year>2017</Year>\n                <Month>10</Month>\n                <Day>18</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2017</Year>\n                <Month>11</Month>\n                <Day>03</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2017</Year>\n                <Month>11</Month>\n                <Day>14</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2018</Year>\n                <Month>8</Month>\n                <Day>1</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2017</Year>\n                <Month>11</Month>\n                <Day>14</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">29131988</ArticleId>\n            <ArticleId IdType="pii">S0960-9776(17)30773-7</ArticleId>\n            <ArticleId IdType="doi">10.1016/j.breast.2017.11.003</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'